A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.

An important trial by Schwartzberg et al. has recently been published in The Oncologist. In prospective manner, this trial tested the two erythropoietin preparations commonly used in the US, epoetin alfa and darbepoetin alfa, in their most commonly used doses and schemas in anemic cancer patients on chemotherapy. The two drugs performed with remarkably similar […]

Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production.

This is an important EPO trial in hematologic malignancy patients for two reasons. It demonstrates that lower EPO levels predict response… an observation not reproduced in solid tumor patients but important to remember in hematologic malignancy patients. It also demonstrates that a weekly dose of EPO, here at a 30,000 U level, is comparable to […]

Iron administration and clinical outcomes in hemodialysis patients.

This study raises two important questions: First, are the observed adverse events upon high dose iron dextran users due to confounding variables such as comorbidity, or are they true iron dextran effects? Second, if they are true iron dextran effects, are they caused by the iron or the dextran? – C. Gasche.

Considerations for optimal iron use for anemia due to chronic kidney disease.

It is certainly of great value to have an overview about different iron regimens in combination with rHuEPO. However, at least in Europe, there is common agreement that parenteral iron and, if used as such, iron sucrose is the gold standard in combination with rHuEPO as regards safety and effectiveness. Monitoring of efficiency is based […]